Difficulties in recovering kidney function and precautions after taking Bikken Pronol Tablets (Bituvi)

Biktarvy tablets (Biktarvy) is a tablet containing bictegravir (Bictegravir), propofovir fumarate (TAF) and emtricitabine (FTC), a three-in-one anti-HIV compound drug, is widely used due to its significant efficacy and convenience of oral administration once a day. Although Biktarvy is generally well tolerated, its TAF component is excreted through the kidneys, and patients with long-term use or existing renal insufficiency still need to pay attention to renal safety. Once a patient develops renal function abnormalities while taking medication, the difficulty of recovery mainly depends on the degree of damage, duration of medication, and the presence of other nephrotoxic factors.

Clinical data show that the renal function damage caused by Biktarvy is mostly mild to moderate elevation of blood creatinine or mild abnormality of renal tubular function, which can usually be gradually recovered after stopping the drug or adjusting the dose. Severe kidney injury is relatively rare, but for patients with pre-existing chronic kidney disease or concurrent use of other nephrotoxic drugs, the recovery process may be slower and may even require combined intervention, such as suspending other drugs that may aggravate kidney injury, optimizing water and electrolyte management, and closely monitoring kidney function. Early detection of changes in kidney function can significantly shorten recovery time and prevent further damage.

In actual medication management, regular monitoring of renal function indicators is key. Patients should evaluate glomerular filtration rate (eGFR), serum creatinine and urine routine before starting treatment with Biktarvy, and maintain frequent monitoring during the initial treatment and during follow-up. If serum creatinine continues to increase or eGFR decreases, the doctor should be informed promptly to assess whether the dose needs to be adjusted or temporarily discontinued, and other factors that may lead to a decline in renal function should be investigated, such as infection, dehydration, or combined use of nonsteroidal anti-inflammatory drugs (NSAIDs).

In addition, in order to reduce the risk of renal damage, patients should pay attention to daily management, including maintaining good hydration, avoiding the abuse of nephrotoxic drugs, and controlling basic diseases such as hypertension and diabetes. Rational medication use, regular follow-up and early intervention are important measures to ensure the stability of renal function and ensure the sustained efficacy of Biktarvy. In general, if kidney function is mildly impaired, timely treatment and monitoring can usually lead to recovery, but high-risk patients still need individualized management to ensure that the HIV viral load can be controlled while protecting kidney health.

Reference:https://reference.medscape.com/